<SEC-DOCUMENT>0001140361-25-004783.txt : 20250214
<SEC-HEADER>0001140361-25-004783.hdr.sgml : 20250214
<ACCEPTANCE-DATETIME>20250214161022
ACCESSION NUMBER:		0001140361-25-004783
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250214
DATE AS OF CHANGE:		20250214

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Q32 Bio Inc.
		CENTRAL INDEX KEY:			0001661998
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				473468154
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-90433
		FILM NUMBER:		25628644

	BUSINESS ADDRESS:	
		STREET 1:		830 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		781-999-0232

	MAIL ADDRESS:	
		STREET 1:		830 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Homology Medicines, Inc.
		DATE OF NAME CHANGE:	20151228

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRISTOL MYERS SQUIBB CO
		CENTRAL INDEX KEY:			0000014272
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				220790350
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		ROUTE 206 AND PROVINCE LINE ROAD
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08543
		BUSINESS PHONE:		6092524621

	MAIL ADDRESS:	
		STREET 1:		ROUTE 206 AND PROVINCE LINE ROAD
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08543

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRISTOL MYERS CO
		DATE OF NAME CHANGE:	19891012
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0001140361-24-046452</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0000014272</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>1</amendmentNo>
<securitiesClassTitle>Common stock, par value $0.0001 per share</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001661998</issuerCik>
<issuerName>Q32 Bio Inc.</issuerName>
<issuerCusip>746964105</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>830 Winter Street</com:street1>
<com:city>Waltham</com:city>
<com:stateOrCountry>MA</com:stateOrCountry>
<com:zipCode>02451</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>BRISTOL MYERS SQUIBB CO</reportingPersonName>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>200244</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>200244</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>200244</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>1.64</classPercent>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<comments>Calculated based upon 12,180,701 shares of common stock, par value $0.0001 per share, outstanding as of November 1, 2024, as reported on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 7, 2024</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Q32 Bio Inc.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>830 Winter Street, Waltham, Massachusetts, 02451</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>This statement is filed by the Bristol-Myers Squibb Company, referred to herein as the "Reporting Person."</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>Route 206 &amp; Province Line Road
Princeton, NJ 08543</principalBusinessOfficeOrResidenceAddress>
<citizenship>See response to Item 4 on the cover page</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>See response to Item 9 on the cover page.</amountBeneficiallyOwned>
<classPercent>See response to Item 11 on the cover page.</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>See response to Item 5 on the cover page.</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>See response to Item 6 on the cover page.</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>See response to Item 7 on the cover page.</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>See response to Item 8 on the cover page.</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>N</notApplicableFlag>
<classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>Y</notApplicableFlag>
</item10>
</items>
<signatureInformation>
<reportingPersonName>BRISTOL MYERS SQUIBB CO</reportingPersonName>
<signatureDetails>
<signature>/s/ Amy Fallone</signature>
<title>Amy Fallone, Corporate Secretary</title>
<date>02/14/2025</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
